Sanofi Expands MS Portfolio With BTK Inhibitor From Principia
Executive Summary
The French pharma adds the Phase I candidate to its Lemtrada follow-on for multiple sclerosis development, while Principia will use $40m in upfront cash to advance its orphan disease strategy.
You may also be interested in...
Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn
Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.
IPO Update: August Had A Slow Start, But New US Filings Hint At Busy September
There were only two biopharma IPOs in the US during August, bringing the year's total to 47. But with eight new filings in August, launches in September could rival July's total of nine first-time offerings, especially since this average return on this year's IPOs remains in positive territory.
Deal Watch: Genentech Expands Upon Arvinas PROTAC Collaboration
The Roche affiliate doubles the potential monetary value of partnership focused on PROTAC technology in a range of therapeutic areas. Cardinal sells off Chinese business for $1.2bn, while Novartis licenses Homology’s gene-editing technology.